Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
- Autores
- Sánchez, Ariel; Brun, Lucas Ricardo Martín; Salerni, H.; Costanzo, P. R.; Gonzalez, D.; Bagur, Alicia Cristina; Oliveri, María Beatriz; Zanchetta, M. B.; Farias, V.; Maffei, L.; Premrou, V.; Mansur, J. L.; larroude, M. S.; Sarli, M. A.; Rey, P.; Ulla, M. R.; Pavlove, M. M.; Karlsbrum, S.; Brance, María Lorena
- Año de publicación
- 2016
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-na�ve patients (BP-na�ve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-na�ve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean � SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-na�ve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-na�ve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.
Fil: Sánchez, Ariel. Centro de Endocrinología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Brun, Lucas Ricardo Martín. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina
Fil: Salerni, H.. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo ; Argentina
Fil: Costanzo, P. R.. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo ; Argentina
Fil: Gonzalez, D.. Mautalen Salud E Investigación; Argentina
Fil: Bagur, Alicia Cristina. Mautalen Salud E Investigación; Argentina
Fil: Oliveri, María Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina. Mautalen Salud E Investigación; Argentina
Fil: Zanchetta, M. B.. Universidad del Salvador; Argentina
Fil: Farias, V.. Universidad del Salvador; Argentina
Fil: Maffei, L.. Consultorios Asociados de Endocrinología Dra. Laura Maffei; Argentina
Fil: Premrou, V.. Consultorios Asociados de Endocrinología Dra. Laura Maffei; Argentina
Fil: Mansur, J. L.. Centro de Endocrinología y Osteoporosis; Argentina
Fil: larroude, M. S.. Cesar Milstein Hospital; Argentina
Fil: Sarli, M. A.. Universidad del Salvador; Argentina
Fil: Rey, P.. Universidad del Salvador; Argentina
Fil: Ulla, M. R.. Centro de Endocrinología y Osteopatías Médicas; Argentina
Fil: Pavlove, M. M.. Hospital Durand; Argentina
Fil: Karlsbrum, S.. Hospital Durand; Argentina
Fil: Brance, María Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Centro de Reumatología; Argentina - Materia
-
DENOSUMAB
BONE MINERAL DENSITY - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/55323
Ver los metadatos del registro completo
id |
CONICETDig_52887b8b5b4a7ed59d84d4e29c519ceb |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/55323 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with OsteoporosisSánchez, ArielBrun, Lucas Ricardo MartínSalerni, H.Costanzo, P. R.Gonzalez, D.Bagur, Alicia CristinaOliveri, María BeatrizZanchetta, M. B.Farias, V.Maffei, L.Premrou, V.Mansur, J. L.larroude, M. S.Sarli, M. A.Rey, P.Ulla, M. R.Pavlove, M. M.Karlsbrum, S.Brance, María LorenaDENOSUMABBONE MINERAL DENSITYhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-na�ve patients (BP-na�ve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-na�ve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean � SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-na�ve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-na�ve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.Fil: Sánchez, Ariel. Centro de Endocrinología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Brun, Lucas Ricardo Martín. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; ArgentinaFil: Salerni, H.. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo ; ArgentinaFil: Costanzo, P. R.. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo ; ArgentinaFil: Gonzalez, D.. Mautalen Salud E Investigación; ArgentinaFil: Bagur, Alicia Cristina. Mautalen Salud E Investigación; ArgentinaFil: Oliveri, María Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina. Mautalen Salud E Investigación; ArgentinaFil: Zanchetta, M. B.. Universidad del Salvador; ArgentinaFil: Farias, V.. Universidad del Salvador; ArgentinaFil: Maffei, L.. Consultorios Asociados de Endocrinología Dra. Laura Maffei; ArgentinaFil: Premrou, V.. Consultorios Asociados de Endocrinología Dra. Laura Maffei; ArgentinaFil: Mansur, J. L.. Centro de Endocrinología y Osteoporosis; ArgentinaFil: larroude, M. S.. Cesar Milstein Hospital; ArgentinaFil: Sarli, M. A.. Universidad del Salvador; ArgentinaFil: Rey, P.. Universidad del Salvador; ArgentinaFil: Ulla, M. R.. Centro de Endocrinología y Osteopatías Médicas; ArgentinaFil: Pavlove, M. M.. Hospital Durand; ArgentinaFil: Karlsbrum, S.. Hospital Durand; ArgentinaFil: Brance, María Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Centro de Reumatología; ArgentinaHindawi Limited2016-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/55323Sánchez, Ariel; Brun, Lucas Ricardo Martín; Salerni, H.; Costanzo, P. R.; Gonzalez, D.; et al.; Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis; Hindawi Limited; Journal of Osteoporosis; 2016; 8-2016; 1-62042-0064CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1155/2016/8738959info:eu-repo/semantics/altIdentifier/url/https://www.hindawi.com/journals/jos/2016/8738959/info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:53:13Zoai:ri.conicet.gov.ar:11336/55323instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:53:13.444CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
title |
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
spellingShingle |
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis Sánchez, Ariel DENOSUMAB BONE MINERAL DENSITY |
title_short |
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
title_full |
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
title_fullStr |
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
title_full_unstemmed |
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
title_sort |
Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis |
dc.creator.none.fl_str_mv |
Sánchez, Ariel Brun, Lucas Ricardo Martín Salerni, H. Costanzo, P. R. Gonzalez, D. Bagur, Alicia Cristina Oliveri, María Beatriz Zanchetta, M. B. Farias, V. Maffei, L. Premrou, V. Mansur, J. L. larroude, M. S. Sarli, M. A. Rey, P. Ulla, M. R. Pavlove, M. M. Karlsbrum, S. Brance, María Lorena |
author |
Sánchez, Ariel |
author_facet |
Sánchez, Ariel Brun, Lucas Ricardo Martín Salerni, H. Costanzo, P. R. Gonzalez, D. Bagur, Alicia Cristina Oliveri, María Beatriz Zanchetta, M. B. Farias, V. Maffei, L. Premrou, V. Mansur, J. L. larroude, M. S. Sarli, M. A. Rey, P. Ulla, M. R. Pavlove, M. M. Karlsbrum, S. Brance, María Lorena |
author_role |
author |
author2 |
Brun, Lucas Ricardo Martín Salerni, H. Costanzo, P. R. Gonzalez, D. Bagur, Alicia Cristina Oliveri, María Beatriz Zanchetta, M. B. Farias, V. Maffei, L. Premrou, V. Mansur, J. L. larroude, M. S. Sarli, M. A. Rey, P. Ulla, M. R. Pavlove, M. M. Karlsbrum, S. Brance, María Lorena |
author2_role |
author author author author author author author author author author author author author author author author author author |
dc.subject.none.fl_str_mv |
DENOSUMAB BONE MINERAL DENSITY |
topic |
DENOSUMAB BONE MINERAL DENSITY |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-na�ve patients (BP-na�ve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-na�ve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean � SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-na�ve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-na�ve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed. Fil: Sánchez, Ariel. Centro de Endocrinología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Brun, Lucas Ricardo Martín. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas; Argentina Fil: Salerni, H.. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo ; Argentina Fil: Costanzo, P. R.. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo ; Argentina Fil: Gonzalez, D.. Mautalen Salud E Investigación; Argentina Fil: Bagur, Alicia Cristina. Mautalen Salud E Investigación; Argentina Fil: Oliveri, María Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina. Mautalen Salud E Investigación; Argentina Fil: Zanchetta, M. B.. Universidad del Salvador; Argentina Fil: Farias, V.. Universidad del Salvador; Argentina Fil: Maffei, L.. Consultorios Asociados de Endocrinología Dra. Laura Maffei; Argentina Fil: Premrou, V.. Consultorios Asociados de Endocrinología Dra. Laura Maffei; Argentina Fil: Mansur, J. L.. Centro de Endocrinología y Osteoporosis; Argentina Fil: larroude, M. S.. Cesar Milstein Hospital; Argentina Fil: Sarli, M. A.. Universidad del Salvador; Argentina Fil: Rey, P.. Universidad del Salvador; Argentina Fil: Ulla, M. R.. Centro de Endocrinología y Osteopatías Médicas; Argentina Fil: Pavlove, M. M.. Hospital Durand; Argentina Fil: Karlsbrum, S.. Hospital Durand; Argentina Fil: Brance, María Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Centro de Reumatología; Argentina |
description |
The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-na�ve patients (BP-na�ve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-na�ve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean � SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-na�ve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-na�ve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-08 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/55323 Sánchez, Ariel; Brun, Lucas Ricardo Martín; Salerni, H.; Costanzo, P. R.; Gonzalez, D.; et al.; Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis; Hindawi Limited; Journal of Osteoporosis; 2016; 8-2016; 1-6 2042-0064 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/55323 |
identifier_str_mv |
Sánchez, Ariel; Brun, Lucas Ricardo Martín; Salerni, H.; Costanzo, P. R.; Gonzalez, D.; et al.; Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis; Hindawi Limited; Journal of Osteoporosis; 2016; 8-2016; 1-6 2042-0064 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1155/2016/8738959 info:eu-repo/semantics/altIdentifier/url/https://www.hindawi.com/journals/jos/2016/8738959/ |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Hindawi Limited |
publisher.none.fl_str_mv |
Hindawi Limited |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269209399132160 |
score |
13.13397 |